Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 11/20 | 0.47 |
| ▸ | LOX | P28300 | 3/20 | 0.47 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.47 |
| ▸ | ECE2 | P0DPD6 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31367022 | 1.00 | LOXL2 (0.47) | LOXL2LOXLOXL3ECE2ROCK1 | |
| Hydrochloric Acid SCHEMBL28952754 | 0.98 | LOXL2 (0.45) | LOXL2LOXLOXL3ECE2ROCK1 | |
| SCHEMBL2859216 | 0.83 | TAAR1 (0.45) | LOXL2ECE2SHMT2ADRB2 | |
| SCHEMBL3387430 | 0.79 | NOS3 (0.50) | LOXL2ADRB2NOS1NOS2 | |
| SCHEMBL7029899 | 0.79 | ECE2 (0.46) | ECE2SHMT2 | |
| SCHEMBL843959 | 0.77 | ECE2 (0.45) | ECE2SHMT2 | |
| SCHEMBL6763074 | 0.77 | ECE2 (0.49) | ECE2SHMT2 | |
| SCHEMBL3820906 | 0.77 | ECE2 (0.45) | ECE2SHMT2 | |
| SCHEMBL9611255 | 0.77 | ECE2 (0.45) | ECE2SHMT2 | |
| SCHEMBL2056360 | 0.77 | NOS3 (0.52) | ECE2SHMT2NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727932-A1 | SMALL MOLECULE LIGANDS AND APTAMERS | MeiraGTx Gene Regulation Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| EP-4635568-A2 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA Pharmaceuticals Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3672954-B1 | COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARM INC (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2024256870-A1 | SMALL MOLECULE LIGANDS AND APTAMERS | MEIRAGTX UK II LIMITED (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | ACADIA PHARMACEUTICALS INC. (US) | 2024-11-12 | — | — | US | disclosed |
| WO-2024165017-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | 成都先导药物开发股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11535597-B2 | Photoreactive ligands and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | ACADIA PHARMACEUTICALS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| WO-2013029830-A1 | POROUS MATERIALS CONTAINING BUILT-IN SINGLE MOLECULE TRAPS FOR SMALL MOLECULE CAPTURE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | WEI ZHI-LIANG (US) | 2012-06-14 | — | — | US | disclosed |
| US-8076345-B2 | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof | EVOTEC AG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
| EP-2139334-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7592345-B2 | Piperazine and [1,4]diazepan derivatives as NK antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535597-B2 | Photoreactive ligands and uses thereof | CLTB, CRYAB, CRYAA | LOXL2 1923/4885LOX 2441/4885LOXL3 1695/4885 |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | LOXL2 4319/4885LOX 4119/4885LOXL3 2019/4885 |
| US-20220298151-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | LOXL2 1837/4885LOX 734/4885LOXL3 1743/4885 |
| US-12139477-B2 | Compounds, salts thereof and methods for treatment of diseases | SLC10A1, CYP27A1, CYP11B2 | LOXL2 1837/4885LOX 734/4885LOXL3 1743/4885 |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | IL1B, IL1A, CRHR1 | LOXL2 3056/4885LOX 2553/4885LOXL3 3780/4885 |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | CNR2, CNR1, CBR1 | LOXL2 1725/4885LOX 1236/4885LOXL3 2542/4885 |
| US-20250197385-A1 | COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES | SLC10A1, CYP27A1, CYP11B2 | LOXL2 1837/4885LOX 734/4885LOXL3 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.